Literature DB >> 26231297

Homozygosity for the common GAA gene splice site mutation c.-32-13T>G in Pompe disease is associated with the classical adult phenotypical spectrum.

Olimpia Musumeci1, Andrea Thieme2, Kristl G Claeys3, Stephan Wenninger4, Rudolf A Kley5, Marius Kuhn6, Zoltan Lukacs7, Marcus Deschauer8, Michele Gaeta9, Antonio Toscano1, Dieter Gläser6, Benedikt Schoser10.   

Abstract

Homozygosity for the common Caucasian splice site mutation c.-32-13T>G in intron 1 of the GAA gene is rather rare in Pompe patients. We report on the clinical, biochemical, morphological, muscle imaging, and genetic findings of six adult Pompe patients from five unrelated families with the c.-32-13T>G GAA gene mutation in homozygous state. All patients had decreased GAA activity and elevated creatine kinase levels. Five patients, aged between 43 and 61 years (median 53 years), initially presented with myalgia, hyperCKaemia, and/or exercise induced fatigue at an age of onset (12-55 years). All but one had proximal lower limb weakness combined with axial weakness and moderate respiratory insufficiency; the sixth patient presented with hyperCKaemia only. Muscle biopsies showed PAS-positive vacuolar myopathy with lysosomal changes and reduced GAA activity. Muscle MRI of lower limb muscles revealed a moderate adipose substitution of the gluteal muscles, biceps femoris and slight fatty infiltration of all thigh muscles. One MRI of the respiratory muscles revealed a diaphragmatic atrophy with unilateral diaphragm elevation. So, the common Caucasian, so called mild, splice site mutation c.-32-13T>G in intron 1 of the GAA gene in a homozygote status reflects the full adult Pompe disease phenotype severity spectrum.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  GAA mutation; GAA-MLPA; Glycogen storage disease type 2; Homozygosity; Pompe disease

Mesh:

Substances:

Year:  2015        PMID: 26231297     DOI: 10.1016/j.nmd.2015.07.002

Source DB:  PubMed          Journal:  Neuromuscul Disord        ISSN: 0960-8966            Impact factor:   4.296


  15 in total

1.  Liquid Chromatography-Tandem Mass Spectrometry Assay of Leukocyte Acid α-Glucosidase for Post-Newborn Screening Evaluation of Pompe Disease.

Authors:  Na Lin; Jingyu Huang; Sara Violante; Joseph J Orsini; Michele Caggana; Erin E Hughes; Colleen Stevens; Lisa DiAntonio; Hsuan Chieh Liao; Xinying Hong; Farideh Ghomashchi; Arun Babu Kumar; Hui Zhou; Ruth Kornreich; Melissa Wasserstein; Michael H Gelb; Chunli Yu
Journal:  Clin Chem       Date:  2017-02-14       Impact factor: 8.327

Review 2.  Molecular genetics of Pompe disease: a comprehensive overview.

Authors:  Paolo Peruzzo; Eleonora Pavan; Andrea Dardis
Journal:  Ann Transl Med       Date:  2019-07

Review 3.  Diagnostic tools in late onset Pompe disease (LOPD).

Authors:  Olimpia Musumeci; Antonio Toscano
Journal:  Ann Transl Med       Date:  2019-07

Review 4.  Pompe Disease: From Basic Science to Therapy.

Authors:  Lara Kohler; Rosa Puertollano; Nina Raben
Journal:  Neurotherapeutics       Date:  2018-10       Impact factor: 7.620

5.  Sensitivity of whole exome sequencing in detecting infantile- and late-onset Pompe disease.

Authors:  Mari Mori; Gloria Haskell; Zoheb Kazi; Xiaolin Zhu; Stephanie M DeArmey; Jennifer L Goldstein; Deeksha Bali; Catherine Rehder; Elizabeth T Cirulli; Priya S Kishnani
Journal:  Mol Genet Metab       Date:  2017-10-17       Impact factor: 4.797

6.  Insight into the phenotype of infants with Pompe disease identified by newborn screening with the common c.-32-13T>G "late-onset" GAA variant.

Authors:  Mugdha V Rairikar; Laura E Case; Lauren A Bailey; Zoheb B Kazi; Ankit K Desai; Kathryn L Berrier; Julie Coats; Rachel Gandy; Rebecca Quinones; Priya S Kishnani
Journal:  Mol Genet Metab       Date:  2017-09-19       Impact factor: 4.797

7.  Quantitative analysis of upright standing in adults with late-onset Pompe disease.

Authors:  Maria Stella Valle; Antonino Casabona; Agata Fiumara; Dora Castiglione; Giovanni Sorge; Matteo Cioni
Journal:  Sci Rep       Date:  2016-11-15       Impact factor: 4.379

8.  Identification of GAA variants through whole exome sequencing targeted to a cohort of 606 patients with unexplained limb-girdle muscle weakness.

Authors:  Katherine Johnson; Ana Töpf; Marta Bertoli; Lauren Phillips; Kristl G Claeys; Vidosava Rakocevic Stojanovic; Stojan Perić; Andreas Hahn; Paul Maddison; Ela Akay; Alexandra E Bastian; Anna Łusakowska; Anna Kostera-Pruszczyk; Monkol Lek; Liwen Xu; Daniel G MacArthur; Volker Straub
Journal:  Orphanet J Rare Dis       Date:  2017-11-17       Impact factor: 4.123

9.  Correlation of GAA Genotype and Acid-α-Glucosidase Enzyme Activity in Hungarian Patients with Pompe Disease.

Authors:  Aniko Gal; Zoltán Grosz; Beata Borsos; Ildikó Szatmari; Agnes Sebők; Laszló Jávor; Veronika Harmath; Katalin Szakszon; Livia Dezsi; Eniko Balku; Zita Jobbagy; Agnes Herczegfalvi; Zsuzsanna Almássy; Levente Kerényi; Maria Judit Molnar
Journal:  Life (Basel)       Date:  2021-05-31

10.  Identification a novel mononucleotide deletion mutation in GAA in pompe disease patients.

Authors:  Milad Ebrahimi; Mahdieh Behnam; Nafiseh Behranvand-Jazi; Ladan Yari; Sajad Sheikh-Kanlomilan; Mansoor Salehi; Pardis Tahmasebi; Mohaddeseh Amini; Mohaddeseh Behjati; Nafisehsadat Hosseini
Journal:  J Res Med Sci       Date:  2017-08-16       Impact factor: 1.852

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.